Severe pazopanib-induced hepatotoxicity: Clinical and histologic course in two patients

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages

  Klempner, Samuel J ^a   Choueiri, Toni K ^b   Yee, Eric ^a   Doyle, Leona A ^c   Schuppan, Detlef ^a   Atkins, Michael B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT INJURY; CASE REPORT; CLEAR CELL CARCINOMA; DRUG INDUCED DISEASE; EOSINOPHIL; HISTIOCYTE; HUMAN; KIDNEY METASTASIS; KUPFFER CELL; LIVER BIOPSY; LIVER HISTOLOGY; LIVER TOXICITY; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALE; NEUTROPHIL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT;

AGED; CARCINOMA, RENAL CELL; DRUG-INDUCED LIVER INJURY; FATAL OUTCOME; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866750660     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.0332     Document Type: Article

References (14)

1. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/ 1975-2008/
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007 (Pubitemid 46148091)
3. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 353:2477-2490, 2005 (Pubitemid 41770167)
4. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991-5004, 2004 (Pubitemid 46646218)
5. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III Trial. J Clin Oncol 28:1061-1068, 2010
6. GlaxoSmithKline. Votrient (pazopanib) tablets prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022465lbl.pdf
7. Kapadia S, Hapani S, Wu S: Risk of high-grade liver toxicity with pazopanib in patients with cancer: A meta-analysis. J Clin Oncol 29: 2011 (suppl; abstr 4595)
8. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
9. Escudier B, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318, 2009
10. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999 (Pubitemid 29368255)
11. Lee WM: Drug-induced hepatotoxicity. N Engl J Med 349:474-485, 2003
12. Kaplowitz N: Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 22:137-144, 2002
13. Xu CF, Reck BH, Goodman VL, et al: Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 54:1237-1243, 2011
14. Keisner S, Shah S: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71:443-454, 2011